Senores Pharmaceuticals Makes Waves—Secures Wockhardt’s Enalapril ANDA for U.S. Push
Updated: May 20, 2025 16:45
Image Source: Pharma Industrial India
Senores Pharmaceuticals Limited made news in its recent acquisition, marking an aggressive push in the U.S. cardiovascular generics market. Senores, in turn, acquired Wockhardt Limited's USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets (2.5 mg, 5 mg, 10 mg, and 20 mg).
Key Highlights:
Strategic Acquisition: Senores' ANDA for Enalapril Maleate, a common drug used in hypertension, heart failure, and asymptomatic left ventricular dysfunction, advances Senores' cardiovascular portfolio and market presence in the U.S.
Market Opportunity: The U.S. market for Enalapril Maleate Tablets is large with recent estimates running $28.6 million (IQVIA, Dec 2024) to $109.24 million (Symphony, Mar 2025) reflecting strong demand and growth potential.
Funding and IPO Synergy: The acquisition will be funded from proceeds of Senores' recent initial public offering, consistent with the company's articulated objective to increase its U.S. product offerings and capitalize on new market opportunities.
Growth Path: The action follows as Senores continues to establish itself as a research-based pharmaceutical manufacturer, penetrating both regulated and emerging markets with a broad product pipeline.
Industry Impact: With the purchase of a USFDA-approved ANDA from a market leader such as Wockhardt, Senores stands to boost its pace of foray into the U.S. generics space that is highly competitive and increase shareholder value.
Through the acquisition, Senores Pharmaceuticals shall take advantage of increased demand for cardiovascular therapies and solidify its focus on expansion worldwide.
Sources: Business Upturn, Moneycontrol, Rediff Money